已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Efficacy, safety, and optimal intervention of belimumab for proliferative lupus nephritis patients in real-world settings: LOOPS registry

医学 狼疮性肾炎 贝里穆马布 内科学 干预(咨询) 重症监护医学 免疫学 疾病 B细胞激活因子 抗体 B细胞 精神科
作者
H. Sakai,Yusuke Miyazaki,Shingo Nakayamada,Satoshi Kubo,Kentaro Hanami,Shunsuke Fukuyo,Ayako Yamaguchi,Ippei Miyagawa,M Ueno,Hiroaki Tanaka,Yasuyuki Todoroki,Naoaki Ohkubo,Masashi Funada,Satsuki Matsunaga,Yoshiya Tanaka
出处
期刊:Rheumatology [Oxford University Press]
标识
DOI:10.1093/rheumatology/keae495
摘要

Abstract Objectives This study investigated the efficacy, safety and predictive factors of belimumab (BEL) in induction therapy for patients with proliferative lupus nephritis (LN) in real-world settings. Methods Patients with biopsy-proven ISN/RPS class III or IV LN, with or without coexisting class V LN, who underwent standard of care (SoC), glucocorticoid (GC) and either mycophenolate mofetil or cyclophosphamide treatments were included. Participants were treated with SoC (SoC group, n = 32) or BEL and SoC (BEL+SoC group, n = 30). The primary end point was complete renal response (CRR) at 52 weeks. Results Baseline patient characteristics were not significantly different between the two groups. The 52-week retention rate of BEL was 90.0%. The BEL+SoC group showed significantly higher CRR and primary efficacy renal response achievement at 52 weeks and significantly lower GC dosage, adverse events and Systemic Lupus International Collaborating Clinics damage index scores. Multivariate analysis of CRR achievement at 52 weeks revealed that the lack of estimated glomerular filtration rate (eGFR) improvement at 4 weeks was associated with CRR failure in the SoC group. A shorter duration (cut-off of 42 days) between the start of induction therapy and addition of BEL was also related to the CRR in the BEL+SoC group. Conclusion BEL, in addition to SoC, controls disease activity, reduces GC use and suppresses organ damage in case of proliferative LN. Earlier BEL induction within 6 weeks may help achieve CRR in treatment-resistant cases without eGFR improvement at 4 weeks after induction therapy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
SciGPT应助wukong采纳,获得10
刚刚
1秒前
4秒前
6秒前
8秒前
9秒前
Rain完成签到,获得积分10
9秒前
李爱国应助科研通管家采纳,获得10
11秒前
小马甲应助科研通管家采纳,获得10
11秒前
深情安青应助科研通管家采纳,获得10
11秒前
天天快乐应助科研通管家采纳,获得10
11秒前
彭于晏应助科研通管家采纳,获得10
11秒前
丘比特应助科研通管家采纳,获得10
11秒前
Rondab应助科研通管家采纳,获得30
11秒前
11秒前
FashionBoy应助科研通管家采纳,获得10
11秒前
13秒前
一直向前发布了新的文献求助10
14秒前
14秒前
可爱的函函应助mellow采纳,获得10
14秒前
17秒前
17秒前
TRY发布了新的文献求助10
18秒前
毕业论文三万字完成签到,获得积分10
19秒前
JOY发布了新的文献求助10
21秒前
momo发布了新的文献求助10
21秒前
晗晗有酒窝完成签到,获得积分10
21秒前
缥缈的碧曼完成签到,获得积分10
22秒前
斯文败类应助Steven采纳,获得10
23秒前
24秒前
25秒前
天天快乐应助大喵采纳,获得10
26秒前
mellow发布了新的文献求助10
28秒前
29秒前
29秒前
非也非也6发布了新的文献求助10
29秒前
JOY完成签到,获得积分10
30秒前
猫瓜西完成签到,获得积分10
30秒前
整齐凝竹完成签到 ,获得积分10
34秒前
35秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989811
求助须知:如何正确求助?哪些是违规求助? 3531927
关于积分的说明 11255560
捐赠科研通 3270706
什么是DOI,文献DOI怎么找? 1805035
邀请新用户注册赠送积分活动 882181
科研通“疑难数据库(出版商)”最低求助积分说明 809190